Monthly newsletter: Read the latest issue
Learn more about our degree programs and admission requirements
Find the information you need to conduct your research and academic studies
See KCUMB's beautiful campus
See faculty research interests
See five-year campus master plan
There are several ongoing clinical trials at KCUMB. To learn more about participating, visit our Volunteer Education Center. If you do not see a study below that interests you, you may still sign up for future studies.
Select a category or scroll down to see all studies now enrolling:
AIDS/HIVAsthmaAllergies, SeasonalCardiovascularCholesterolChronic Back PainChronic Bronchitis
COPDDiabetesEmphysemaFibromyalgiaGastro-esophageal RefluxHigh CholesterolHypertension/High Blood Pressure
Infectious DiseaseInfluenzaIrritable Bowel SyndromePregnancyReactive Airway Disorder
We are conducting a research study to test the safety and efficacy of an experimental drug in subjects with high cholesterol. The experimental drug will be administered by subcutaneous injection once every two weeks. The purpose of the study is to compare the effects of the experimental study drug to those of a placebo in lowering cholesterol in patients who are already taking medication to lower their cholesterol. A placebo looks like the study drug but does not contain the study drug’s active ingredients.
This study will last for about 20 months, and there are at least 15 visits to the Center. If you qualify to be in the study, you will receive $75.00 for each visit you complete. During the study visits you can expect various routine procedures like, vital signs, physical exam, ECG, lab work, etc. to be performed. Each visit will last approximately 45 minutes except for the screening visit, which will last approximately 2 hours.
Description: A phase 3 double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy, long-term safety and tolerability of PF-04950615 in subjects with primary hyperlipidemia or mixed dyslipidemia at risk of cardiovascular events.
Contact Information: Center for Community and Clinical Research, firstname.lastname@example.org or 1-877-425-0250
Description: D5896C00027 | A 26 week, randomized, double-blind, parallel-group, active controlled, multicenter, multinational safety study evaluating the risk of serious asthma-related events during treatment with Symbicort®, a fixed combination of inhaled corticosteroid (ICS) (budesonide) and a long acting β2-agonist (LABA) (formoterol) as compared to treatment with ICS (budesonide) alone in adult and adolescent (≥12 years of age) patients with asthma.Contact Information: Center for Community and Clinical Research, email@example.com or 1-877-425-0250.
KCUMB’s Center for Community and Clinical Research is currently recruiting subjects for a 12-month outpatient study of an investigational diabetes medication. Compensation is available for time and travel.
Description: NN1218-3852 | Efficacy and safety of FIAsp compared to insulin aspart both in combination with insulin detemir in adults with Type 1 diabetes. Contact Information: Center for Community and Clinical Research, firstname.lastname@example.org or 1-877-425-0250.
Description: A randomized, double-blind, placebo-controlled, event-driven trial of weekly low-dose methotrexate (LDM) in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with type 2 diabetes or metabolic syndrome. Contact Information: Center for Community and Clinical Research, email@example.com or 1-877-425-0250.
1750 Independence AvenueKansas City, Mo. 64106-14531-800-234-4847 | 816-654-7000